Rodman & Renshaw analyst Elemer Piros downgraded Alto Neuroscience (ANRO) to Neutral from Buy with a $5.50 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience price target lowered to $10 from $32 at Baird
- Alto Neuroscience CEO says ‘strong cash balance to support us’
- Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint
- Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint
- Alto Neuroscience falls -3.8%